DCGA recommends emergency use authorization of Russian Vaccine, Sputnik-V

sputnik v

The Expert panel of the Central drug regulator, DCGA has recommended emergency use authorisation to the Russian Vaccine, Sputnik-V. After necessary approval from the DCGA, Sputnik-V will be the third vaccine to get emergency use authorisation from the drug regulator after Covishield and Covaxin. The clinical trial of the vaccine in India is being done by Dr Reddy’s Lab. The Hyderabad based, multinational Indian pharma company, Dr. Reddy’s Lab has also inked an agreement with the Russian Direct Investment Fund, RDIF for supply of the Russian vaccine in India.

    Leave a Reply

    Your email address will not be published. Required fields are marked *